Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. https://doi.org/10.3322/CA.2007.0010

Article  PubMed  Google Scholar 

Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16. https://doi.org/10.1016/S0140-6736(20)30314-7

Article  CAS  PubMed  Google Scholar 

Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209. https://doi.org/10.1007/s00259-014-2949-6

Article  CAS  PubMed  Google Scholar 

Werner P, Neumann C, Eiber M, Wester HJ, Schottelius M. [(99 cm)tc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center. EJNMMI Res. 2020;10:45. https://doi.org/10.1186/s13550-020-00635-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.

CAS  PubMed  Google Scholar 

Cornelio DB, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol. 2007;18:1457–66. https://doi.org/10.1093/annonc/mdm058

Article  CAS  PubMed  Google Scholar 

Mansi R, Fleischmann A, Macke HR, Reubi JC. Targeting GRPR in urological cancers–from basic research to clinical application. Nat Rev Urol. 2013;10:235–44. https://doi.org/10.1038/nrurol.2013.42

Article  CAS  PubMed  Google Scholar 

Roesler R, Henriques JA, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target for psychiatric and neurological disorders. CNS Neurol Disord Drug Targets. 2006;5:197–204. https://doi.org/10.2174/187152706776359673

Article  CAS  PubMed  Google Scholar 

Beer M, Montani M, Gerhardt J, Wild PJ, Hany TF, Hermanns T, et al. Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates. Prostate. 2012;72:318–25. https://doi.org/10.1002/pros.21434

Article  CAS  PubMed  Google Scholar 

Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, et al. Pilot comparison of (6)(8)Ga-RM2 PET and (6)(8)Ga-PSMA-11 PET in patients with biochemically recurrent prostate Cancer. J Nucl Med. 2016;57:557–62. https://doi.org/10.2967/jnumed.115.168393

Article  CAS  PubMed  Google Scholar 

Liolios C, Schafer M, Haberkorn U, Eder M, Kopka K. Novel Bispecific PSMA/GRPr Targeting Radioligands with optimized pharmacokinetics for improved PET imaging of prostate Cancer. Bioconjug Chem. 2016;27:737–51. https://doi.org/10.1021/acs.bioconjchem.5b00687

Article  CAS  PubMed  Google Scholar 

Kurth J, Krause BJ, Schwarzenbock SM, Bergner C, Hakenberg OW, Heuschkel M. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [(177)Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47:123–35. https://doi.org/10.1007/s00259-019-04504-3

Article  CAS  PubMed  Google Scholar 

Mather SJ, Nock BA, Maina T, Gibson V, Ellison D, Murray I, et al. GRP receptor imaging of prostate cancer using [(99m)tc]demobesin 4: a first-in-man study. Mol Imaging Biol. 2014;16:888–95. https://doi.org/10.1007/s11307-014-0754-z

Article  PubMed  Google Scholar 

Ananias HJ, Yu Z, Hoving HD, Rosati S, Dierckx RA, Wang F, et al. Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7–14) SPECT/CT in prostate cancer patients: a first-in-man study. Nucl Med Biol. 2013;40:933–8. https://doi.org/10.1016/j.nucmedbio.2013.05.009

Article  CAS  PubMed  Google Scholar 

Gunther T, Konrad M, Stopper L, Kunert JP, Fischer S, Beck R, et al. Optimization of the Pharmacokinetic Profile of [(99m)tc]Tc-N(4)-Bombesin derivatives by modification of the pharmacophoric gln-trp sequence. Pharmaceuticals (Basel). 2022;15. https://doi.org/10.3390/ph15091133

Ferrer L, Kraeber-Bodere F, Bodet-Milin C, Rousseau C, Le Gouill S, Wegener WA, et al. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer. 2010;116:1093–100. https://doi.org/10.1002/cncr.24797

Article  CAS  PubMed  Google Scholar 

Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689–94.

CAS  PubMed  Google Scholar 

Kletting P, Schimmel S, Hanscheid H, Luster M, Fernandez M, Nosske D, et al. The NUKDOS software for treatment planning in molecular radiotherapy. Z Med Phys. 2015;25:264–74. https://doi.org/10.1016/j.zemedi.2015.01.001

Article  PubMed  Google Scholar 

Kletting P, Schimmel S, Kestler HA, Hanscheid H, Luster M, Fernandez M, et al. Molecular radiotherapy: the NUKFIT software for calculating the time-integrated activity coefficient. Med Phys. 2013;40:102504. https://doi.org/10.1118/1.4820367

Article  CAS  PubMed  Google Scholar 

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2005;46:1023–7.

Google Scholar 

The 2007 Recommendations of the International Commission on Radiological Protection. Ann ICRP. 2007;37:1–332. https://doi.org/10.1016/j.icrp.2007.10.003. ICRP publication 103.

Koller L, Joksch M, Schwarzenbock S, Kurth J, Heuschkel M, Holzleitner N, et al. Preclinical comparison of the (64)Cu- and (68)Ga-Labeled GRPR-Targeted compounds RM2 and AMTG, as Well as First-in-humans [(68)Ga]Ga-AMTG PET/CT. J Nucl Med. 2023. https://doi.org/10.2967/jnumed.123.265771

Article  PubMed  PubMed Central  Google Scholar 

Haendeler M, Khawar A, Ahmadzadehfar H, Kürpig S, Meisenheimer M, Essler M, et al. Biodistribution and Radiation Dosimetric Analysis of [68Ga]Ga-RM2: a potent GRPR antagonist in prostate carcinoma patients. Radiation. 2020;1:33–44. https://doi.org/10.3390/radiation1010004

Article  Google Scholar 

Pfob CH, Ziegler S, Graner FP, Kohner M, Schachoff S, Blechert B, et al. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:1962–70. https://doi.org/10.1007/s00259-016-3424-3

Article  CAS  PubMed  Google Scholar 

Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40:s37–61.

Google Scholar 

Stabin MG, Wendt RE 3rd, Flux GD. RADAR guide: Standard Methods for Calculating Radiation Doses for Radiopharmaceuticals, Part 1-Collection of Data for Radiopharmaceutical Dosimetry. J Nucl Med. 2022;63:316–22. https://doi.org/10.2967/jnumed.120.259200

Article  PubMed  Google Scholar 

Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane Antigen Positron Emission Tomography in Advanced prostate Cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane Antigen-avid lesions: a systematic review and Meta-analysis. Eur Urol. 2020;77:403–17. https://doi.org/10.1016/j.eururo.2019.01.049

Article  PubMed  Google Scholar 

Ruigrok EAM, Verhoeven M, Konijnenberg MW, de Blois E, de Ridder CMA, Stuurman DC, et al. Safety of [(177)Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity. Eur J Nucl Med Mol Imaging. 2022;49:4440–51. https://doi.org/10.1007/s00259-022-05926-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pretze M, Reffert L, Diehl S, Schonberg SO, Wangler C, Hohenberger P, et al. GMP-compliant production of [(68)Ga]Ga-NeoB for Positron emission tomography imaging of patients with gastrointestinal stromal tumor. EJNMMI Radiopharm Chem. 2021;6:22. https://doi.org/10.1186/s41181-021-00137-w

Article  PubMed  PubMed Central  Google Scholar 

Montemagno C, Raes F, Ahmadi M, Bacot S, Debiossat M, Leenhardt J, et al. In vivo biodistribution and efficacy evaluation of NeoB, a Radiotracer targeted to GRPR, in mice bearing gastrointestinal stromal tumor. Cancers (Basel). 2021;13. https://doi.org/10.3390/cancers13051051

Stoykow C, Erbes T, Maecke HR, Bulla S, Bartholoma M, Mayer S, et al. Gastrin-releasing peptide receptor imaging in breast Cancer using the receptor antagonist (68)Ga-RM2 and PET. Theranostics. 2016;6:1641–50. https://doi.org/10.7150/thno.14958

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morgat C, MacGrogan G, Brouste V, Velasco V, Sevenet N, Bonnefoi H, et al. Expression of gastrin-releasing peptide receptor in breast Cancer and its Association with Pathologic, Biologic, and clinical parameters: a study of 1,432 primary tumors. J Nucl Med. 2017;58:1401–7. https://doi.org/10.2967/jnumed.116.188011

Article  CAS  PubMed  Google Scholar 

Roivainen A, Kahkonen E, Luoto P, Borkowski S, Hofmann B, Jambor I, et al. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013;54:867–72. https://doi.org/10.2967/jnumed.112.114082

Article  CAS  PubMed  Google Scholar 

Gnesin S, Cicone F, Mitsakis P, Van der Gucht A, Baechler S, Miralbell R, et al. First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist (68)Ga-NODAGA-MJ9. EJNMMI Res. 2018;8:108. https://doi.org/10.1186/s13550-018-0462-9

Article  PubMed  PubMed Central  Google Scholar 

Zhang J, Niu G, Fan X, Lang L, Hou G, Chen L, et al. PET using a GRPR antagonist (68)Ga-RM26 in healthy volunteers and prostate Cancer patients. J Nucl Med. 2018;59:922–8. https://doi.org/10.2967/jnumed.117.198929

Article  CAS  PubMed  PubMed Central